MICHAEL SCHEURER to Risk Assessment
This is a "connection" page, showing publications MICHAEL SCHEURER has written about Risk Assessment.
Connection Strength
0.413
-
Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2019 03; 28(3):555-562.
Score: 0.082
-
Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients. Clin Cancer Res. 2018 10 15; 24(20):5012-5017.
Score: 0.081
-
Neurocognitive functioning and genetic variation in patients with primary brain tumours. Lancet Oncol. 2016 Mar; 17(3):e97-e108.
Score: 0.068
-
Anti-human-cytomegalovirus immunoglobulin G levels in glioma risk and prognosis. Cancer Med. 2013 Feb; 2(1):57-62.
Score: 0.055
-
Epidemiologic differentiation of diagnostic and screening populations for the assessment of cervical dysplasia using optical technologies. Gend Med. 2012 Feb; 9(1 Suppl):S36-47.
Score: 0.051
-
Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int J Cancer. 2011 Nov 01; 129(9):2290-6.
Score: 0.048
-
Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes. Head Neck. 2016 09; 38(9):1330-7.
Score: 0.017
-
Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol. 2010 May 10; 28(14):2467-74.
Score: 0.011